115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
Charlson 合并症指数对接受经皮冠状动脉介入治疗冠状动脉疾病患者短期和长期预后的影响
Authors Ma Y, Luo H, Zhao H, Zhao O, Ma L , Yang W, Yi M, Sun L, Li J
Received 1 September 2025
Accepted for publication 28 December 2025
Published 14 January 2026 Volume 2026:22 559412
DOI https://doi.org/10.2147/TCRM.S559412
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Yixin Ma, Hongyu Luo, Huan Zhao, Ou Zhao, Lina Ma, Wei Yang, Ming Yi, Lijie Sun, Jing Li
Department of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, 100053, People’s Republic of China
Correspondence: Jing Li, Department of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, No. 45 Changchun Street, Xicheng District, Beijing, 100053, People’s Republic of China, Email shpxbb@sina.com
Background: The Charlson Comorbidity Index (CCI) is widely used to assess comorbidity burden, its prognostic role in patients undergoing percutaneous coronary intervention (PCI) remains underexplored. This study aimed to investigate the impact of CCI on in-hospital adverse events and long-term major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with coronary artery disease (CAD) treated with PCI.
Methods: A total of 572 consecutive CAD patients who underwent PCI between October 2016 and October 2020 were included. Patients were divided into low (CCI ≤ 4, n = 453) and high (CCI > 4, n = 119) comorbidity burden groups. Clinical characteristics, in-hospital adverse events, and long-term MACCEs were compared. Multivariate logistic regression and Cox proportional hazards models were used to identify independent predictors of outcomes.
Results: Compared to the low-CCI group, patients in the high-CCI group were older, more frequently male, and had higher rates of diabetes, left main CAD, and multivessel disease (all p < 0.05). In-hospital adverse events were significantly more common in the high-CCI group (13.4% vs 2.0%, p < 0.01). CCI was an independent predictor of in-hospital events (OR = 3.13; 95% CI: 1.40– 7.02). During a median follow-up of five years, the high-CCI group had a significantly higher incidence of MACCEs (51.3% vs 6.2%; HR = 2.72; 95% CI: 2.25– 3.30, p < 0.01).
Conclusion: CCI is a significant and independent predictor of both in-hospital and long-term adverse outcomes in CAD patients undergoing PCI.
Keywords: Charlson comorbidity index, coronary artery disease, percutaneous coronary intervention, in-hospital adverse events, major adverse cardiovascular and cerebrovascular events, prognostic evaluation
Department of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, 100053, People’s Republic of China
Correspondence: Jing Li, Department of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, No. 45 Changchun Street, Xicheng District, Beijing, 100053, People’s Republic of China, Email shpxbb@sina.com
Background: The Charlson Comorbidity Index (CCI) is widely used to assess comorbidity burden, its prognostic role in patients undergoing percutaneous coronary intervention (PCI) remains underexplored. This study aimed to investigate the impact of CCI on in-hospital adverse events and long-term major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with coronary artery disease (CAD) treated with PCI.
Methods: A total of 572 consecutive CAD patients who underwent PCI between October 2016 and October 2020 were included. Patients were divided into low (CCI ≤ 4, n = 453) and high (CCI > 4, n = 119) comorbidity burden groups. Clinical characteristics, in-hospital adverse events, and long-term MACCEs were compared. Multivariate logistic regression and Cox proportional hazards models were used to identify independent predictors of outcomes.
Results: Compared to the low-CCI group, patients in the high-CCI group were older, more frequently male, and had higher rates of diabetes, left main CAD, and multivessel disease (all p < 0.05). In-hospital adverse events were significantly more common in the high-CCI group (13.4% vs 2.0%, p < 0.01). CCI was an independent predictor of in-hospital events (OR = 3.13; 95% CI: 1.40– 7.02). During a median follow-up of five years, the high-CCI group had a significantly higher incidence of MACCEs (51.3% vs 6.2%; HR = 2.72; 95% CI: 2.25– 3.30, p < 0.01).
Conclusion: CCI is a significant and independent predictor of both in-hospital and long-term adverse outcomes in CAD patients undergoing PCI.
Keywords: Charlson comorbidity index, coronary artery disease, percutaneous coronary intervention, in-hospital adverse events, major adverse cardiovascular and cerebrovascular events, prognostic evaluation